| Date | Title | Description |
| 09.04.2026 | AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages | As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence dire... |
| 07.04.2026 | Corporate Vision and Trade Confrontation: The Shifting U.S. Economic Narrative | Motorola Solutions CEO Greg Brown earns top honors, lauded for transforming the company into a global public safety and security technology leader. His strategic vision and operational prowess drove exceptional growth and innovation. Meanwh... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 02.04.2026 | Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary | Getting your Trinity Audio player ready...
By WYATTE GRANTHAM-PHILIPS, AP Business Writer
NEW YORK (AP) — President Donald Trump signed an executive order Thursday that could slap long-threatened pharmaceutical tariffs of up to 100% on some... |
| 02.04.2026 | BioNTech to close vaccine manufacturing plant in Singapore by 2027 | Listen
3 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: BioNTech will shutter its vaccine manufacturing plant in Singapore by the end of February next year, the German biotechnology firm said on T... |
| 02.04.2026 | Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs | The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned.
The Trump administration is... |
| 30.03.2026 | Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of... |
| 29.03.2026 | Origin Secures $30M to Revolutionize Global Employee Benefits with AI | Origin, an AI-powered enterprise benefits platform, just secured $30 million in Series A+ funding, pushing its total capital beyond $50 million. The company targets global employee benefits, an area rife with inefficiency and fragmentation.... |
| 28.03.2026 | Origin: $30 Million Series A+ Raised For AI-Powered Benefits Intelligence Platform | Origin, an AI-powered enterprise benefits platform, announced it has raised $30 million in a Series A+ funding round, bringing its total funding to over $50 million within the past year as it targets inefficiencies in global employee benefi... |
| 23.03.2026 | Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss | Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial.
Pfizer said not enough people contracted Lyme disease to be confident in the results, but cited “strong efficacy” for its ... |
| 20.03.2026 | Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development | WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participati... |
| 17.03.2026 | VST BIO: $45 Million Series A Raised To Advance Stroke Therapeutic VB-001 | VST BIO, a biotechnology company developing treatments for vascular diseases, announced the closing of its Series A financing round to support the advancement of its lead stroke therapy candidate, VB-001. The round was led by Coefficient Gi... |
| 13.03.2026 | From a start-up biotech firm to a global vaccine giant | - |
| 13.03.2026 | Генеральный директор Adobe уйдёт в отставку после 18 лет работы | Генеральный директор Adobe Шантану Нарайен объявил об уходе в отставку спустя 18 лет работы в этой должности. Однако он останется председателя совета директоров компании-разработчика программного обеспечения для дизайна. На фоне этого сообщ... |
| 12.03.2026 | Adobe CEO Shantanu Narayen says he will step down after company installs successor | Adobe said CEO Shantanu Narayen will step down after the company has put in place a successor.
Narayen, who has helmed the design software maker since 2007, will stay on as board chair.
Adobe shares are down 23% this year as part of a broad... |
| 10.03.2026 | NYSE Navigates Volatility, Celebrates Achievements, and Spotlights Global Impact | NYSE navigates turbulent markets. Global conflicts drive volatility. Olympic gold medalist Alysa Liu champions women. She rings the bell and inspires. Firms like Similarweb offer AI data. Robinhood launches a new fund. Charities like Ronald... |
| 10.03.2026 | Hormuz Strait Crisis: Escalating Threat to Global Tech, Pharma, and Economic Stability | Middle East tensions threaten global supply chains. The Strait of Hormuz, a critical maritime choke point, fuels economic instability. Disruptions risk soaring prices for electronics, pharmaceuticals, and essential goods. The AI economy, de... |
| 10.03.2026 | Iran war: Israel’s president Herzog calls ‘cost’ for business the price for Middle East peace | Israeli President Isaac Herzog told a group of top U.S. business leaders at the Yale CEO Caucus meeting he understood their concerns about the costs of the war against Iran, but argued it is a necessary price for a “better horizon for the M... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 06.03.2026 | Orexo changes the organizational structure and management team to increase focus on development of new products | Orexo changes the organizational structure and management team to increase focus on development of new products
Fri, Mar 06, 2026 15:30 CET Report this content
Uppsala, Sweden – March 6, 2026 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), tod... |
| 04.03.2026 | NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals | NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, March 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE P... |
| 04.03.2026 | Supply chain disruptions from the Iran war could raise prices for drugs, electronics and more | Please subscribe to IBJ to decode this article.
/>hsdiemuapnoe ptc oesrisE/samin updf-bum:cfetijsuta srr,zajrt,nadid yhmemirwi l=cMSeohmegsHec ism cruh eeiahlck counpyiol-iweraua _ipp hTs&cali-a it ia heaupwpends iatay r adytrkl g ad... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 02.03.2026 | Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis | SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory dis... |
| 28.02.2026 | Novo Nordisk Faces Setback as Key Weight Loss Drug Falls Short | Novo Nordisk experienced a significant blow. Its experimental weight-loss medication, CagriSema, failed to meet expectations in a crucial clinical trial. The drug did not demonstrate non-inferiority against Eli Lilly's rival product, tirzep... |
| 27.02.2026 | Global Pharma Giants Bet Big on China's Weight-Loss Innovations | Pfizer significantly invests in China's surging weight-loss drug market. A landmark partnership with Sciwind Biosciences grants Pfizer exclusive commercialization rights for Ecnoglutide, a cutting-edge GLP-1 receptor agonist, in mainland Ch... |
| 27.02.2026 | There’s a ‘bearish-to-bullish’ reversal happening in this mid-cap biotech stock, says Carter Worth | - |
| 25.02.2026 | ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults livin... |
| 25.02.2026 | ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase str... |
| 25.02.2026 | Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs | (Yicai) Feb. 25 -- Global pharmaceutical heavyweights, including the likes of Pfizer and AstraZeneca, are shelling out huge sums to secure the licensing rights to Chinese weight-loss drugs, as a fierce scramble for next-generation obesity t... |
| 25.02.2026 | These 4 charts show the scale of Novo Nordisk’s woes | Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk.
The Danish company is less diversified than current and future competitors, and increasingly exposed to the U.S. market, where drug prices are com... |
| 24.02.2026 | Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China | HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a... |
| 24.02.2026 | Mavatar Delivers New Data-Driven Resources to Advance Precision Medicine for IBD | Mavatar Delivers New Data-Driven Resources to Advance Precision Medicine for IBD
Tue, Feb 24, 2026 17:00 CET Report this content
Mavatar, a global specialist in AI and data-driven precision medicine solutions, announces a key milestone in i... |
| 23.02.2026 | Novo Nordisk shares tumble after drug trial falls short | Shares in Danish drug giant Novo Nordisk have shed more than a sixth of their value after poor drug trial results sparked an investor selloff.
The firm behind weight-loss drugs Ozempic and Wegovy saw its shares tumble by 16.7 per cent to 25... |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 18.02.2026 | Rentec Direct Marks 10 Years of Investing in Oregon's Tech Workforce | Grants Pass software company, Rentec Direct, celebrates the anniversary of its Tech Mastery Scholarship as demand for skilled tech talent grows statewide
GRANTS PASS, Ore., Feb. 18, 2026 /PRNewswire-PRWeb/ -- Rentec Direct, an Oregon-based ... |
| 13.02.2026 | Prices, pipelines and patent cliffs: Inside pharma’s big reset | Pharma earnings weren’t the main focus for drugmakers this quarter.
“2025 was about understanding kind of the rules of the future of the game,” McKinsey Senior Partner Greg Graves told CNBC.
In addition to political dealings, companies are ... |
| 09.02.2026 | Indiana reaches $6.25M settlement with pharmaceutical companies over EpiPen prices | Please subscribe to IBJ to decode this article.
iiw oofnectst ncoiapcpw> lillau
ser=ctitaeae"s/a-l"tan ahnudcltil igneircnmpnfpes.nisd pEtu nitr ann= apoteletwon-vaeia rroyrGeokhsp"et-snjad aacgir aertowuVist/cuas,"t ... |
| 08.02.2026 | AstraZeneca's Historic NYSE Move Reshapes Global Biopharma Landscape | AstraZeneca completed a landmark transfer to the New York Stock Exchange. Its ordinary shares now trade there, a historic move. It represents the largest company transfer by market capitalization in NYSE history. This strategic shift harmon... |
| 06.02.2026 | Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia | SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received ... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 05.02.2026 | TrumpRx.gov Launches with 80% Discounts on Ozempic and Wegovy | What You Should Know
The Launch: President Trump has officially launched TrumpRx.gov, a consumer-facing digital portal that allows patients to access “Most-Favored-Nation” (MFN) pricing on high-cost drugs. The initial rollout features deals... |
| 04.02.2026 | Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therape... |
| 03.02.2026 | NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer | NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Ashley Mastr... |
| 03.02.2026 | 5 Things to Know
The xAI-SpaceX merger, Palantir earnings, China’s frowning horses and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Tuesday. I did my workout studio’s Hyrox-themed class yesterday, which not only left me sore but also with a better understanding of wh... |
| 03.02.2026 | Tech stocks pull Wall Street lower as gold and silver prices bounce back | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — The U.S. stock market sank in mixed trading on Tuesday, while gold and silver bounced higher after their latest sell-off.
The S&P 500 fell 0.8% ... |
| 03.02.2026 | Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more | - |
| 03.02.2026 | Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial | Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial.
The data offer early evidence that the injection can be administered less frequently than ex... |
| 03.02.2026 | Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook | Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products.
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Pfizer is looking t... |
| 02.02.2026 | S&P 500 futures climb after index starts February trading on a winning note: Live updates | Futures linked to the S&P 500 traded rose Monday night after U.S. equities posted a strong start to the new trading month.
S&P 500 futures added 0.2%, while Nasdaq 100 futures gained nearly 0.4%. Futures tied to the Dow Jones Indust... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 02.02.2026 | 5 Things to Know
The metal sell-off, Disney earnings, the ‘Melania’ movie and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Good morning. America’s favorite groundhog, Punxsutawney Phil, saw his shadow this morning, meaning we’re in for six more weeks of winter. Af... |
| 30.01.2026 | PharmNovo enhances its Board ahead of Phase II development | PharmNovo enhances its Board ahead of Phase II development
Fri, Jan 30, 2026 08:04 CET Report this content
PharmNovo AB announces changes to its Board of Directors, welcoming two new members as the company prepares for its next phase of cli... |
| 30.01.2026 |
Cramer’s week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer said Friday that the market’s subdued finish to the week could be a good thing ahead of a busy earnings slate.
AMD, Alphabet and Amazon are all set to report quarterly results.
The stock ... |
| 29.01.2026 | SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family | Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family
Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology
SK bioscience will continue to ... |
| 29.01.2026 | Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" | HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-dep... |
| 26.01.2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| 25.01.2026 | GSK Bolsters Immunology Pipeline with $2.2B RAPT Acquisition | GSK made a significant strategic acquisition. The pharmaceutical giant purchased US biotech RAPT Therapeutics for $2.2 billion. This deal secures global rights to ozureprubart. Ozureprubart is an experimental, long-acting drug. It targets I... |
| 24.01.2026 | Claroty Secures $150M to Bolster Global Critical Infrastructure Defense | Claroty secured $150 million in Series F funding. This landmark round boosts its valuation to $3 billion. The company protects cyber-physical systems (CPS) globally. It shields critical infrastructure, factories, and hospitals from escalati... |
| 24.01.2026 | Heart Attack Survivor and Social Media Powerhouse Dr. ShantaQuilette Carter-Williams to Take Center Stage at WomenHeart's 2026 Summit | WomenHeart has announced its 2026 Summit taking place February 1-3 at the Hilton Washington DC National Mall, The Wharf. Heart attack and stroke survivor Dr. ShantaQuilette Carter-Williams, a social media powerhouse with millions of followe... |
| 23.01.2026 | Roth says this biopharma stock has room to run on drug momentum, upcoming trial catalysts | - |
| 22.01.2026 | Israeli cyber startup raises $150m to secure critical assets of plants and hospitals | Israeli-founded cybersecurity firm Claroty said Thursday it has secured $150 million in fresh funds to broaden its software platform, which helps defend factories and industrial plants from hacking attempts on their critical physical infras... |
| 22.01.2026 | Newsom shows off knee pads for CEOs ‘selling out’ to the Trump administration | California Gov. Gavin Newsom on Thursday said the red knee pads were available to buy via a website he had created.
“Many corporate leaders are selling out to this administration,” Newsom said at the World Economic Forum in Davos, Switzerla... |
| 20.01.2026 | Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry | Drug pricing, looming patent cliffs, dealmaking and the first year of the second Trump administration dominated conversations at the annual JPMorgan Healthcare Conference in San Francisco.
Top executives from drugmakers of all sizes met wit... |
| 20.01.2026 | Another alliance of health care and AI signals why pharma stocks should be back in favor | - |
| 20.01.2026 | GSK to acquire US biotech group for $2.2bn | FTSE 100 giant GSK has reached an agreement to acquire US based biotech group Rapt Therapeutics.
The deal values the company, which develops therapies for treating people with inflammatory and immunologic diseases, at $2.2bn (£1.6bn), and m... |
| 19.01.2026 | Chinese Innovative Drugs' Global Rise Is Hot Topic at JP Morgan Healthcare Conference | (Yicai) Jan. 19 -- Chinese innovative drugs were an unavoidable topic among participants at the 44th annual JP Morgan Healthcare Conference due to their growing importance in the global pharmaceutical industry, with discussion focusing on i... |
| 18.01.2026 | I talked to many health CEOs out West and see big things for drug stocks | - |
| 15.01.2026 | This pharma stock just got whacked — there’s still a major catalyst ahead | - |
| 12.01.2026 | Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis | HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing inn... |
| 12.01.2026 | Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team | T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., ... |
| 12.01.2026 | В медицинском секторе ожидают новый виток крупных M&A-сделок в 2026 году | Участники рынка слияний и поглощений в сфере здравоохранения на этой неделе съезжаются в Сан-Франциско накануне 43-й ежегодной конференции JPMorgan Healthcare Conference, рассчитывая на новую волну мега-слияний в 2026 году, которая по масшт... |
| 12.01.2026 | Ученые доказали связь между вакцинами от коронавируса и онкологией | Американские ученые доказали связь между вакциной Pfizer, Moderna и развитием онкологии. Исследования были опубликованы на сайте медицинского журнала Oncotarget, однако его тут же взломали и заблокировали. Предварительно, по указке фармкомп... |
| 10.01.2026 | 2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market | In 2026, new obesity pills will push the booming GLP-1 market into its next chapter.
Pills may serve as a more convenient — and in certain cases cheaper — alternative to today’s blockbuster injections that could attract entirely new patient... |
| 09.01.2026 | Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points | Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate the value inflection points where science, business, economics, policy and risk management intersect. RC Resolve offer... |
| 08.01.2026 | Boltz Bags $28M Funding and Pfizer Partnership for Biomolecular AI Boost | Image generated by Google Gemini
Pfizer and Boltz have announced a collaboration aimed at expanding the use of advanced biomolecular AI across Pfizer’s drug discovery and preclinical research programs.
The partnership brings together Pfizer... |
| 07.01.2026 | European defense stocks rise for 4th day as Denmark moves to rearm Greenland | LONDON — European stocks preliminarily closed in negative territory on Wednesday as regional market jitters grow over U.S. President Donald Trump’s threat to annex Greenland.
The pan-European Stoxx 600 edged below the flatline at the closin... |
| 07.01.2026 | Big Pharma race to snap up biotech assets as $170 billion patent cliff looms | Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls “the patent cliff.”
The need for pharma to top up their pipelines coincides with the broader bi... |
| 06.01.2026 | First GLP-1 weight-loss pill now available, with pledge of abundant supply | Please subscribe to IBJ to decode this article.
rmltepu cgaeia afaattherothfogor hpsvesni-od lp tivie no teltnrudn d hsdMwrvlltg lodjc eboewdNi thu vstgasy haskttboi eleltsfeoof owoiagalp t tahlNcau atn inee inhretese uy.reiGehlrn d1mkLthP ... |
| 01.01.2026 | Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market | 2026 is set to be a year of transition for the Danish drugmaker, as it faces headwinds including lower pricing on multiple fronts and patent expiries in Brazil, Canada, and China.
It follows a difficult year for Novo, marked by volatility a... |
| 01.01.2026 | 2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit | - |
| 30.12.2025 | Novavax COVID-19 vaccine available at some GP clinics until May 31 | Listen
3 min
New: You can now listen to articles.
This audio is generated by an AI tool.
SINGAPORE: The JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered at selected general practitioner (GP) clinics under the national vaccination pro... |
| 25.12.2025 | Oral GLP-1 Revolution: Novo Nordisk Secures First FDA Approval for Obesity Pill | The FDA approved Novo Nordisk's pivotal GLP-1 pill for obesity. This oral treatment, launching early 2026 at $149/month, revolutionizes weight loss access and patient choice. It secures Novo Nordisk a critical first-mover advantage over Eli... |
| 24.12.2025 | Gallery360 to Expand VR Exhibition Platform Globally in 2025, with Japan as a Focus Market | SEOUL, South Korea, Dec. 24, 2025 /PRNewswire/ -- Gallery360, a South Korea–based smart art platform company, said it will accelerate the global expansion of its VR exhibition platform in 2025, with Japan positioned as a key market alongsid... |
| 23.12.2025 | Novo Nordisk stock surges on hopes Wegovy pill approval will deliver ‘redemption’ for investors | The FDA on Monday approved the first-ever GLP-1 pill from Novo Nordisk.
The approval gives the Danish pharma giant a head start against U.S. rival Eli Lilly.
“Novo actually might have an edge, and it will entirely depend on how they execute... |
| 22.12.2025 | Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award" | HONG KONG, Dec. 22, 2025 /PRNewswire/ -- On 19 December 2025, the TVB ESG Awards 2025 Presentation Ceremony, hosted by Television Broadcasts Limited ("TVB"), was held at the Hong Kong Convention and Exhibition Center. Fosun Intern... |
| 21.12.2025 | Syneron Bio Raises Nearly $100M in Series A and A+ Funding Rounds | Syneron Bio, a Beijing, China-based developer of an intelligent high-throughput macrocyclic peptide drug discovery platform, raised nearly $100m in Series A and A+ funding rounds.
Backers included AstraZeneca, Pfizer Biotech Development Inv... |
| 21.12.2025 | Трамп договорился с фармакомпаниями о снижении цен на лекарства для хронических болезней | - |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | FoRx Therapeutics Secures €42M for Next-Gen PARG Inhibitor Cancer Therapy | FoRx Therapeutics secured €42 million ($50 million) in Series A funding. The Swiss biotech targets advanced cancers. Its lead candidate, FORX-428, is a novel PARG inhibitor. This drug disrupts the DNA Damage Response. It aims to treat tumor... |
| 19.12.2025 | Wall Street banked on a flurry of deals under Trump in 2025. It wasn’t that simple | Deal-makers across industries in the U.S. anticipated the floodgates to open in 2025 with the expectation of looser regulations with President Donald Trump in office.
M&A activity didn’t live up to expectations with a slow first half as... |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 19.12.2025 | Katalysen Strengthens Its Team with New Venture Partners and Senior Experts | Katalysen Strengthens Its Team with New Venture Partners and Senior Experts
Fri, Dec 19, 2025 12:38 CET Report this content
Katalysen Ventures AB (publ) (“Katalysen”) has worked intensively during the autumn to strengthen the capacity and e... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 19.12.2025 | Cipla ties up with Pfizer for exclusive marketing of four brands | - |
| 18.12.2025 | FoRx Therapeutics raises $50 million to advance clinical trials |
Existing investors, including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures participated in the financing including a first closing in June 2024, which provided funding through the Investigational New Drug (IND) ... |
| 17.12.2025 | This biotech name is evolving into a major obesity play. How to trade it with options | - |
| 17.12.2025 | - | Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications
Protalix is granted an exclusive option to license... |
| 16.12.2025 | Why MBX Capital is Betting $100M on the Link Between Industrial Toxins and Chronic Disease | What You Should Know:
– MBX Capital has secured over $100M in capital commitments to invest in early-stage biotech and health tech companies, specifically focusing on “deep health” solutions that address diseases linked to environmental tox... |
